LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

10X Genomics Inc (Class A)

Slēgts

SektorsVeselības aprūpe

29.13 -4.74

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

28.93

Max

30.97

Galvenie mērījumi

By Trading Economics

Ienākumi

2.8M

-13M

Pārdošana

-15M

151M

EPS

0.07

Peļņas marža

-8.93

Darbinieki

1,178

EBITDA

2.5M

-17M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-19.91% downside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.1B

3.9B

Iepriekšējā atvēršanas cena

33.87

Iepriekšējā slēgšanas cena

29.13

Ziņu noskaņojums

By Acuity

50%

50%

154 / 344 Rangs Healthcare

10X Genomics Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. jūn. 23:36 UTC

Peļņas

Correction to Oracle Reports Higher 4Q Profit Article

2026. g. 10. jūn. 23:19 UTC

Karstas akcijas

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026. g. 10. jūn. 23:09 UTC

Galvenie tirgus virzītāji

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026. g. 10. jūn. 23:04 UTC

Peļņas

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026. g. 10. jūn. 20:44 UTC

Galvenie tirgus virzītāji

Caterpillar Raises Quarterly Dividend 8%

2026. g. 10. jūn. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Should Take No Options Off The Table

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026. g. 10. jūn. 23:47 UTC

Tirgus saruna

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026. g. 10. jūn. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026. g. 10. jūn. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 10. jūn. 23:32 UTC

Tirgus saruna

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026. g. 10. jūn. 23:20 UTC

Tirgus saruna

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026. g. 10. jūn. 22:05 UTC

Tirgus saruna

Correction to Bank of Canada Stays on Hold Market Talk

2026. g. 10. jūn. 21:57 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:52 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:35 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:22 UTC

Peļņas

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. jūn. 20:39 UTC

Tirgus saruna
Peļņas

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026. g. 10. jūn. 20:34 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Peļņas

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna
Peļņas

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Salīdzinājums

Cenas izmaiņa

10X Genomics Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

-19.91% uz leju

Prognoze 12 mēnešiem

Vidējais 24.5 USD  -19.91%

Augstākais 32 USD

Zemākais 20 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

3

Pirkt

7

Turēt

0

Pārdot

Noskaņojums

By Acuity

154 / 344 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat